302 related articles for article (PubMed ID: 20051617)
1. Anaemia in older people with chronic heart failure: The potential cost.
Man-Fai Sim V; Nam MC; Riley S; Yousef Z; Hurley J; Cheung WY; O'Mahony S
Technol Health Care; 2009; 17(5-6):377-85. PubMed ID: 20051617
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.
Choy CK; Spencer AP; Nappi JM
Pharmacotherapy; 2007 May; 27(5):707-14. PubMed ID: 17461706
[TBL] [Abstract][Full Text] [Related]
4. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
Bhandari S; Naudeer S
J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
6. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.
Robles NR; Macias JF; Herrera J
Eur J Intern Med; 2014 Feb; 25(2):193-6. PubMed ID: 24491240
[TBL] [Abstract][Full Text] [Related]
8. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
[TBL] [Abstract][Full Text] [Related]
9. The impact of anaemia and kidney function in congestive heart failure and preserved systolic function.
Philipp S; Ollmann H; Schink T; Dietz R; Luft FC; Willenbrock R
Nephrol Dial Transplant; 2005 May; 20(5):915-9. PubMed ID: 15741202
[TBL] [Abstract][Full Text] [Related]
10. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
[TBL] [Abstract][Full Text] [Related]
11. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
12. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
[TBL] [Abstract][Full Text] [Related]
13. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Rossert J; Gassmann-Mayer C; Frei D; McClellan W
Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
[TBL] [Abstract][Full Text] [Related]
15. Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?
Ferrari P; Xiao J; Ukich A; Irish A
Nephrol Dial Transplant; 2009 Jun; 24(6):1828-33. PubMed ID: 19131346
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of chronic kidney disease stages 3-5 among acute medical admissions: another opportunity for screening.
Annear NM; Banerjee D; Joseph J; Harries TH; Rahman S; Eastwood JB
QJM; 2008 Feb; 101(2):91-7. PubMed ID: 18184667
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.
Wong CF; McCarthy M; Howse ML; Williams PS
Ren Fail; 2007; 29(6):653-9. PubMed ID: 17763158
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G; Gârneata L; Capusa C; Ursea N
Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
[TBL] [Abstract][Full Text] [Related]
19. Anaemia in patients with chronic kidney disease: management with epoetin beta in primary care setting in New Zealand.
Madhan KK; Chamberlain M; Anderson E
Nephrology (Carlton); 2008 Oct; 13(5):428-32. PubMed ID: 18331435
[TBL] [Abstract][Full Text] [Related]
20. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]